Business Description
enGene Holdings Inc
NAICS : 541714
SIC : 3741
ISIN : CA29286M1059
Description
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.37 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -104.3 | |||||
| 3-Year EPS without NRI Growth Rate | -73.5 | |||||
| 3-Year FCF Growth Rate | -23.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.78 | |||||
| 9-Day RSI | 63.42 | |||||
| 14-Day RSI | 58.07 | |||||
| 6-1 Month Momentum % | -29.36 | |||||
| 12-1 Month Momentum % | 12.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.52 | |||||
| Quick Ratio | 19.52 | |||||
| Cash Ratio | 19.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 6.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -107.81 | |||||
| ROA % | -79.75 | |||||
| ROIC % | -812.05 | |||||
| ROC (Joel Greenblatt) % | -6175.37 | |||||
| ROCE % | -82.06 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.66 | |||||
| Price-to-Tangible-Book | 1.66 | |||||
| EV-to-EBIT | -1.75 | |||||
| EV-to-Forward-EBIT | -3.16 | |||||
| EV-to-EBITDA | -1.75 | |||||
| EV-to-Forward-EBITDA | -3.16 | |||||
| EV-to-FCF | -5.73 | |||||
| Price-to-Net-Current-Asset-Value | 1.69 | |||||
| Price-to-Net-Cash | 1.73 | |||||
| Earnings Yield (Greenblatt) % | -57.14 | |||||
| FCF Yield % | -8.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
enGene Holdings Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.763 | ||
| Beta | 0 | ||
| Volatility % | 115.71 | ||
| 14-Day RSI | 58.07 | ||
| 14-Day ATR ($) | 0.607593 | ||
| 20-Day SMA ($) | 8.1995 | ||
| 12-1 Month Momentum % | 12.78 | ||
| 52-Week Range ($) | 4.42 - 18.4 | ||
| Shares Outstanding (Mil) | 50.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
enGene Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
enGene Holdings Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
enGene Holdings Inc Frequently Asked Questions
What is enGene Holdings Inc(ENGN)'s stock price today?
The current price of ENGN is $8.65. The 52 week high of ENGN is $18.40 and 52 week low is $4.42.
When is next earnings date of enGene Holdings Inc(ENGN)?
The next earnings date of enGene Holdings Inc(ENGN) is 2024-12-31 Est..
Does enGene Holdings Inc(ENGN) pay dividends? If so, how much?
enGene Holdings Inc(ENGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers